Why the study?
Does catheter ablation improve outcomes in patients with cardiac sarcoidosis and ventricular tachycardia resistant to medical treatment?
Does catheter ablation improve outcomes in patients with cardiac sarcoidosis and ventricular tachycardia resistant to medical treatment?
Catheter ablation may be a viable option for medically refractory ventricular tachycardia in cardiac sarcoidosis, but current evidence is limited to low-quality observational data requiring future randomized trials.
Answers are grounded in this paper and cite their sources.
May support ablation consideration in selected refractory cardiac sarcoidosis VT; leaves open efficacy confirmation by randomized trials.
These data support the utilization of catheter ablation in selected CS cases resistant to medical treatment. However, data are derived from observational non-controlled case series, with low-methodological quality. Therefore, future well-designed, randomized controlled trials, or large-scale registries are required.
No takes yet. Share an insight, caveat, or question.
Παπαγεωργίου et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: